Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

This publication has 15 references indexed in Scilit:

• Gastrointestinal stromal tumors: Recent advances in understanding of their biology
  Published by Elsevier ,2004
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
  European Journal Of Cancer, 2002
• Imatinib Mesylate — A New Oral Targeted Therapy
  New England Journal of Medicine, 2002
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
  The Lancet, 2001
• The histopathological differential diagnosis of gastrointestinal stromal tumours
  Journal of Clinical Pathology, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• The local management of soft tissue sarcoma
  Seminars in Radiation Oncology, 1999
• Importance of Surgical Resection in the Successful Management of Soft Tissue Sarcoma
  Archives of Surgery, 1999
• The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view
  Critical Reviews in Oncology/Hematology, 1995